3 Top Biotech Buyout Candidates in 2021
https://www.fool.com/investing/2021/01/04/3-top-biotech-buyout-candidates-in-2021/
3. Translate BioThanks to the success for COVID-19 vaccines developed by Moderna and the Pfizer-BioNTech partnership, interest in messenger RNA (mRNA) technology is at an all-time high. Don't be surprised if a big drugmaker chooses to scoop up a smaller player to stake a claim in the mRNA space. Translate Bio (NASDAQ:TBIO) could be a top prospect. Granted, Translate Bio is lagging well behind the leaders in the coronavirus vaccine race. The company and its partner, Sanofi (NASDAQ:SNY), plan to begin a phase 1/2 study of mRNA vaccine candidate MRT5500 in Q1 of this year. But the allure of mRNA goes well beyond just COVID-19. Translate Bio's pipeline includes an mRNA therapy targeting cystic fibrosis that's in early stage testing. It also teamed up with Sanofi to develop mRNA vaccines for influenza as well as other viral and bacterial diseases.
Sanofi just might decide that it needs more than just collaboration deals with Translate Bio to remain a major player in the global vaccine market with the rise of mRNA technology. With the small biotech's market cap below $1.5 billion, an acquisition could be on the table in the not-too-distant future.
|